Eisai Sues Teva Over ANDA For Alzheimer’s Drug
The suit was filed in response to Teva’s filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administration.
Teva filed the ANDA in October, sending Eisai a letter on October 24 notifying the Japanese company of its intent to produce a generic version of the drug.
After an ANDA is filed, the patent holder has 45...
To view the full article, register now.